2023 World Conference on Lung Cancer (Posters)-EP11.03. Profile of Patients with NSCLC Who Benefit from Immunochemotherapy. Real-World Data from the Multicenter Polish Lung Cancer Group Study

EP11.03. Profile of Patients with NSCLC Who Benefit from Immunochemotherapy. Real-World Data from the Multicenter Polish Lung Cancer Group Study - PDF(Slides)

Back to course

Pdf Summary

A recent study conducted by the Multicenter Polish Lung Cancer Group has provided real-world data on the profile of patients with non-small cell lung cancer (NSCLC) who benefit from immunochemotherapy. The study focused on patients who received pembrolizumab combined with chemotherapy as first-line treatment for advanced NSCLC.<br /><br />The study found that pembrolizumab combined with chemotherapy demonstrated significant advantages over chemotherapy alone, with approximately 20% of patients showing a five-year survival rate. This confirms the findings of previous trials, such as KEYNOTE-189 and KEYNOTE-407.<br /><br />The study also aimed to identify patient subpopulations that may benefit more from this treatment approach. The inclusion criteria for the study included patients with clinical stage 4 NSCLC, ECOG performance status of 0-1, no EGFR/ALK alterations, no active brain metastases, and no previous PD-1/PD-L1 inhibitors therapy.<br /><br />The results of the study showed an overall disease control rate of 76.6% in the study population. The median progression-free survival (mPFS) was 13 months, and the median overall survival (mOS) was 16.8 months.<br /><br />Further analysis of the data revealed that histology (non-squamous vs squamous) and PD-L1 expression did not significantly impact survival parameters.<br /><br />The study identified several prognostic factors that had a positive impact on overall survival. These factors include ECOG performance status of 0, no liver and bones metastases, neutrophils to lymphocytes ratio less than 3, no body weight loss, and sum of target lesions less than 110mm.<br /><br />In conclusion, this real-world data confirms the efficacy of immunochemotherapy in NSCLC patients, irrespective of age, PD-L1 expression, and histology. The study also suggests that certain clinical factors assessed before treatment initiation can help identify the optimal patient population for this treatment approach.

Asset Subtitle

Magdalena Knetki-Wróblewska

Meta Tag

Speaker Magdalena Knetki-Wróblewska

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

Multicenter Polish Lung Cancer Group

non-small cell lung cancer

NSCLC

immunochemotherapy

pembrolizumab

chemotherapy

first-line treatment

KEYNOTE-189

KEYNOTE-407

patient subpopulations